Forepont Capital Partners
VC Fund
New York, United States
Forepont Capital Partners is a VC fund in New York focused on Medical and Biotechnology. Forepont Capital Partners provides permanent capital to invest in the asset manager and strengthen this partnership. It was founded in 2014 and is based in New York. Forepont's mission is to provide scientific, technological, financial, and operational support to biotech, medtech, and e-health start-ups in the United States and Europe.Forepont boosts its performance by leveraging its talent, expertise, partners, and global ecosystem.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
- Fund size:
- $130M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Forepont Capital Partners invests in
Stages Forepont Capital Partners invests in
Countries Forepont Capital Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bruce Greenberg
|
|||
Eric M. Attias
|
|||
Julien Tizot
|
|||
Investment Focus
Industry
- Medical 5 (33%)
- Biotechnology 4 (27%)
- Medical Device 4 (27%)
- Health Care 3 (20%)
- Pharmaceutical 3 (20%)
Stage
- Series A 6 (40%)
- Series B 3 (20%)
- Series C 2 (13%)
- Seed 1 (7%)
- Venture - Series Unknown 1 (7%)
Country
- France 4 (27%)
- United States 4 (27%)
- Australia 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bruce Greenberg
CFO
|
CFO | Total investments: 0 | Find email | |
|
Eric M. Attias
Managing Partner & Co-Founder
|
Managing Partner & Co-Founder | Total investments: 1 | Find email | |
|
Julien Tizot
General Partner
|
General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Exeliom
|
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France. | $3.3M / Series A / Oct 21, 2025 | |
Okeiro
|
Okeiro offers an AI platform for chronic disease and transplant care, enabling early detection, monitoring, and treatment. | $11.3M / Series A / Apr 10, 2025 | |
AlterDiag
|
AlterDiag mission is to develop and commercialize innovative lateral flow immunochromatographic tests using technologies like single-chain variable fragment antibodies. | $2.1M / Seed / Jan 29, 2025 | |
Precision Neuroscience
|
Precision Neuroscience is a neural platform for next-generation brain-computer interface technology. The company's goal is to provide breakthrough treatments for the one billion patients worldwide suffering from neurological illnesses. Its brain–computer interface is designed to be minimally invasive, safely removable, and capable ofprocessing large amounts of data.The company was founded in 2021 and is based in New York. | $102M / Series C / Nov 06, 2024 | |
GPN Vaccines
|
GPN Vaccines are a type of vaccine that is used to prevent the spread developing a vaccine against streptococcus pneumoniae. | $12M / Series B / Jun 06, 2024 | |
basecamp vascular
|
basecamp vascular is a medtech company that offers a Robotic solution for endovascular navigation. | $6.5M / Series A / Dec 13, 2023 | |
|
GPN Vaccines
|
GPN Vaccines are a type of vaccine that is used to prevent the spread developing a vaccine against streptococcus pneumoniae. | $6.3M / Series A / Jan 31, 2023 | |
|
Precision Neuroscience
|
Precision Neuroscience is a neural platform for next-generation brain-computer interface technology. The company's goal is to provide breakthrough treatments for the one billion patients worldwide suffering from neurological illnesses. Its brain–computer interface is designed to be minimally invasive, safely removable, and capable ofprocessing large amounts of data.The company was founded in 2021 and is based in New York. | $41M / Series B / Jan 25, 2023 | |
Synchron
|
Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic. | $75M / Series C / Dec 16, 2022 | |
|
Synchron
|
Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic. | $75M / Series C / Dec 15, 2022 | |
| See all 15 investments → | |||
Co-Investors
B Capital
3 deals together
ID8 Investments
3 deals together
Khosla Ventures
3 deals together
METIS innovative
3 deals together
Steadview Capital
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Forepont Capital Partners invest in?
Forepont Capital Partners invests primarily in Medical, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Forepont Capital Partners?
Public channels for Forepont Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Forepont Capital Partners?
The team at Forepont Capital Partners includes Bruce Greenberg (CFO), Eric M. Attias (Managing Partner & Co-Founder) and Julien Tizot (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
